New funding fuels Minervax's hope to win strep B vaccine race despite huge competition
Group B strep, which is behind nearly half of life-threatening infections in newborns, has no preventive vaccine. A consortium of investors is hoping to change this by boosting Minervax – which is facing off with a much larger company with equal backing.
by christian bundgaard, translated by daniel pedersen & catherine brett
Danish biotech company Minervax has just raised a staggering EUR 72m – and the company only has one product under development, a vaccine candidate for group B strep.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
UK watchdog to probe antibiotic prices amid strep A outbreak
For subscribers
